Liraglutide for idiopathic intracranial hypertension: a real-world propensity score-matched study
19 Cardiovascular Outcome Trials of SGLTis in Patients with Type 2 Diabetes SGLTis have emerged as potent agents for the reduction in MACE risk, hospitalizations for HF (HFH), and the progression of chronic kidney disease
At AgeWell Medicine & Aesthetics, we provide ongoing support, coaching, and accountability throughout your weight loss journey
After your first order, youll receive login instructions to manage your account and subscription preferences at any time
"Tirzepatide Once Weekly for the Treatment of Obesity." NEJM 2022 (SURMOUNT-1) ClinicalTrials.gov: TRIUMPH Phase 3 program trial protocols and status updates FDA Prescribing Information: Wegovy, Mounjaro/Zepbound, Saxenda (for comparative safety data) Frequently Asked Questions Most side effects peak during dose escalation (weeks 412) and improve substantially by week 24